Please assess the completion status of the following clinical trial:

Trial Title: Radiosurgery for Patients With Oligometastatic Disease at Initial Presentation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pathologically (histologically or cytologically) proven diagnosis of solid malignancy within 8 weeks of registration~2. Eligible disease sites include the following~   * Breast~  * Prostate~  * GI (including colorectal, anal, esophagus, pancreas, gastric with the exception of colon cancer with resectable liver-only lesions)~  * Head and neck~  * Skin (melanoma and squamous cell carcinoma)~  * Lung (both small cell and non-small cell)~  * Sarcoma (both soft tissue and bone)~  * Gynecologic (endometrial, cervical, ovarian, vaginal, vulvar)~3. Patients are stage IV (M1) with any combination of T and N with oligometastatic disease as defined by 5 or fewer total sites of metastatic disease involving 3 or fewer organ systems~1 Examples of patients eligible for trial~* T3N2M1 NSCLC with 1 CNS metastatic lesion, 2 liver lesions, and 1 adrenal lesion.~* T4N1M1 colorectal cancer with 1 liver lesion, 4 bone lesions~* T3N0M1 gastric cancer with 1 supraclavicular lymph node, 2 liver lesions, and 2 CNS lesions 4Metastatic disease sites must be treatable with SRS (at discretion of treating physician).~  5Primary disease site must be able to be treated with curative intent 6Zubrod Performance Status 0-1 7Age ≥ 18 8CBC/differential obtained within 4 weeks prior to registration on study, with adequate bone marrow function defined as follows:~* Absolute neutrophil count (ANC) ≥ 1,800 cells/mm3;~* Platelets ≥ 100,000 cells/mm3;~* Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.); 9Women of childbearing potential and male participants must practice adequate contraception 10Patient must provide study specific informed consent prior to study entry.~Exclusion Criteria:~1. Ineligible disease sites include the following~   * Lymphoma~  * Leukemia~  * Multiple myeloma~  * Primary CNS~  * Peritoneal carcinomatosis~  * Colon cancer with resectable liver-only lesions~2. Examples of patients ineligible for trial~   * T1N1M1 NSCLC with 1 CNS lesion, 1 bone lesion, 1 adrenal lesion and a cervical lymph node (4 sites of metastatic disease)~  * T2N1M1 Gastric cancer with 6 liver lesions (more than 5 sites of metastatic disease)~3. Other~   * Lung cancer with pleural effusion (wet IIIB) are not eligible~  * Recurrent cancers are not eligible~  * Diffuse metastatic spread confined to one organ system is ineligible; examples of this include leptomeningeal spread in the CNS and peritoneal carcinomatosis.~4. Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable but cannot have any other primary cancer diagnosed or treated within the last 3 years other than cutaneous skin cancers. Patient may have previous chemotherapy as treatment of this previous malignancy as long as the chemotherapy has completed more than 3 years ago.~5. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields~6. Severe, active co-morbidity, defined as follows:~   * Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months;~  * Transmural myocardial infarction within the last 6 months;~  * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;~  * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol.~  * Immuno-compromised patients.~7. Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.~8. Oligometastatic disease sites not eligible based on concern for toxicity:~   * trachea involvement (direct invasion, tumors close to or abutting trachea are eligible)~  * heart (direct invasion or involvement, pericardial lymph nodes can be treated)~9. Patients unable to have an FDG-PET/CT scan, either through insurance coverage, patient decision or other reason are not eligible for this study.~10. Patients unable to have SRS through insurance coverage or ability to pay for SRS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stereotactic Body Radiotherapy (SBRT) with/without chemotherapy (Type: EXPERIMENTAL): Sequence of therapy: SRS/SBRT will be used for all sites of metastatic disease in close approximation to initiation of treatment for the primary disease site (within 6 weeks). Ideally, SRS/SBRT would occur first followed by treatment to primary site. However, in some circumstances surgical resection of the primary site could precede SRS/SBRT, especially if surgical resection is required for pathological confirmation of disease.~Chemotherapy choice of agents is at the discretion of the treating medical oncologist; chemotherapy may be initiated after stereotactic radiosurgery treatment of the primary disease site has been completed.

Based on this trial design, predict the completion outcome and termination type (if applicable).